ora™ is the first and only non-invasive endometrial receptivity test for determining the optimal time for embryo transfer.
ora™ assesses over 300 microRNA (miRNA) biomarkers in the blood that target more than 1,000 endometrial receptivity-related genes alongside a patient’s physiological conditions, making it the most comprehensive and accessible solution for identifying a patient’s personalized window of implantation (WOI).
ora™ analyzes miRNA biomarkers in the blood, removing the need for an invasive and uncomfortable endometrial biopsy procedure.
ora™ accounts for both average and shortened post-receptive windows, meaning patients usually only require one mock cycle. If blood samples are taken during a patient’s first IVF cycle, the mock cycle can be potentially avoided altogether.
ora™ as been shown to have > 95% accuracy in predicting endometrial receptivity, offering a stable solution with a more comfortable testing procedure.
ora™ analyzes close to 300 miRNA biomarkers that target over 700 confirmed endometrial receptivity-related genes, along with other physiological conditions to accurately identify the optimal time for embryo transfer.
Unlike other endometrial receptivity tests that use mRNA biomarkers, ora™’s miRNA-based technology gives accurate results from a simple blood sample. miRNA has the added benefit of being more stable than mRNA, meaning re-testing due to insufficient RNA occurs in <1% of cases.
The miRNAs discovered during ora™’s development play a critical role in:
The day 5 blood draw was found to be within the window of implantation (WOI), and is the optimal time for embryo transfer.
The blood was drawn before the WOI, and the endometrium was not yet ready for embryo transfer. It is recommended to delay the embryo transfer cycle by 24 hours.
The blood was drawn after the WOI, and the endometrium had passed the optimal time for embryo implantation. Based on the day 4 and day 5 blood draw results, it is recommended to move the embryo transfer time forward by 12 hours.
The blood was drawn after the WOI, and the endometrium has passed the optimal time for embryo implantation. Based on the day 4 and day 5 blood draw results, it is recommended to move the embryo transfer time forward by 24 hours.
* The need to re-test in the case of inconclusive results or invalid/insufficient RNA in the sample occurs in <1% of cases
ora™ can accurately identify the WOI of any patient, but not every patient needs endometrial receptivity testing. We recommended ora™ for those who meet any of the following conditions:
The likelihood of having a displaced window of implantation increases with the number of implantation failures. Higher successful pregnancy rates have been seen after identification of the patient’s WOI.
Fill out the Sample Submission and Consent Form with your patient (included in the kit).
Schedule the blood draws based on either natural cycles or hormone replacement therapy cycles*.
Use the blood sample collection tubes provided in the kit. Invert the tube 5-10 times immediately after the blood sample has been collected.
The blood samples will be processed into plasma samples onsite within two hours of sample collection according to ora™’s laboratory instructions.
Label the processed blood samples (plasma samples) with the unique sample barcode provided in the kit. Store the tube at -80°C for at least 12 hours.
Ship the package at low temperature or on icepacks to the designated shipping address using priority or next day shipping.
Blood samples should be taken 5 days (120 hours) after starting progesterone administration in an HRT cycle or 7 days (168 hours) after LH surge is detected, or 7 days (168 hours) after hCG administration.
An additional blood draw is highly recommended on day 4 (96 hours) after starting progesterone administration, or day 6 (144 hours) after LH surge or hCG administration in order to reduce the chances of needing an additional mock cycle due to a post-receptive result.
Download our in-depth overview of ora™, or visit our contact page to get in touch directly.
